Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px

Document › Details

Adaptimmune Therapeutics plc. (5/10/17). "Press Release: Adaptimmune Reports First Quarter 2017 Financial Results". Philadeliphia, PA & Oxford.

	Organisation	Adaptimmune Therapeutics plc (Nasdaq: ADAP)
	Group	Adaptimmune (Group)
	Organisation 2	Matrix Capital Management Company L.P.
	Group	Matrix Capital (Group)
	Product	AFP SPEAR™ T-cell therapy
	Product 2	letetresgene autoleucel (NY-ESO SPEAR® T-cell therapy)
	Index term	Adaptimmune–Matrix Capital Management: investment, 201704 direct offering $42m of 7m ADSs at $6/ADS
	Person	Noble, James (Adaptimmune 201909– Non-Executive Director before CEO before MediGene + Avidex)
	Person 2	Tayton-Martin, Helen (Adaptimmune 201703– CBO before COO + Co-Founder before Avidex/Medigene)

Original document
accessed by [iito] on 2017-05-25

Record changed: 2023-06-05

Picture EBD Group ChinaBio Partnering Forum 2023 Shanghai 650x200px

More documents for Adaptimmune (Group)

[1] Adaptimmune Therapeutics plc. (3/6/23). "Press Release: Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors". Philadeliphia, PA, Oxford & Canbridge, MA....
[2] Adaptimmune Therapeutics plc. (11/8/22). "Press Release: Adaptimmune Reports Third-Quarter Financial Results and Business Update". Philadelphia, PA & Oxford....
[3] Adaptimmune Therapeutics plc. (10/25/22). "Press Release: Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK". Philadelphia, PA & Oxford....
[4] Sutura Therapeutics Ltd.. (3/2/20). "Press Release: Sutura Therapeutics Appoints James Noble and Eduardo Bravo to Board of Directors". Birkenhead....
[5] Adaptimmune Therapeutics plc. (1/14/20). "Press Release: Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies". Tokyo, Philadelphia, PA & Oxfordshire....
[6] Adaptimmune Ltd.. (10/5/19). "Press Release: United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4". Philadeliphia, PA & Oxfordshire....
[7] Adaptimmune Ltd.. (10/1/19). "Press Release: Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer". Philadeliphia, PA & Oxfordshire....
[8] Adaptimmune Ltd.. (9/30/19). "Press Release: Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO". Philadeliphia, PA & Oxfordshire....
[9] Adaptimmune Therapeutics plc. (8/27/19). "Press Release: Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products Expressing IL-7 and CCL19 as a Next-generation Treatment for Cancer Patients". Philadeliphia, PA & Oxfordshire....
[10] Vaccitech Ltd.. (8/27/19). "Press Release: Vaccitech Appoints Bill Enright as New Chief Executive Officer". Philadeliphia, PA & Oxfordshire....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]